Gene therapy company Lexeo Therapeutics nabs $100m Series B
Lexeo Therapeutics, a clinical-stage gene therapy company, has secured $100 million in Series B financing.
Lexeo Therapeutics, a clinical-stage gene therapy company, has secured $100 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination